HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Beauty Grows Double Digits On Launches, Promotions In Q3

This article was originally published in The Rose Sheet

Executive Summary

Johnson & Johnson's beauty-care division advanced in the third quarter on the recently acquired Lubriderm brand, new products and "successful" promotional campaigns for Aveeno, Clean & Clear and Neutrogena, the company reported during an Oct. 16 analyst call

You may also be interested in...



NAD Finds Neutrogena’s Superiority Claims For Helioplex Sunscreens Justified

Neutrogena's "best" and "strongest" and "longest-lasting" claims for it Helioplex-containing sun-care products are adequately substantiated, according to a Sept. 18 report from the National Advertising Division (NAD)

J&J Acquires Listerine, Lubriderm As Part Of $16.6 Bil. Pfizer Deal

Johnson & Johnson's successful bid to acquire Pfizer Consumer Healthcare augments the company's oral care division into a billion dollar-plus business and expands the segment's global reach, the company said

Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD

A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015028

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel